Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 Data Strengthens Its Case
Vor Biopharma (VOR) is back in focus after collaborator RemeGen shared fresh Phase 3 data on telitacicept in generalized myasthenia gravis at the 2026 AANEM meeting, highlighting sustained responses and consistent safety.
Vor Biopharma’s latest update lands after a volatile run, with the 1 month share price return down 25.03% and the 1 year total shareholder return falling 43.77%. At the same time, the year to date share price return sits at 61.34%, while longer term total shareholder returns over three and five years remain deeply negative. This suggests that recent momentum is fragile and that fresh clinical data is influencing risk perceptions rather than reversing the broader trend.
Scan beyond Vor Biopharma and review hand-picked autoimmune and biotech players with resilient balance sheets using our list of solid balance sheet and fundamentals (25 results) as a starting universe.
Bulls see telitacicept’s fresh gMG data as a reason Vor Biopharma’s rebound has further to run, while bears focus on deep long term losses and execution risk. Which case does the current valuation lean toward?
Most Popular Narrative: 52% Undervalued
Vor Biopharma’s most followed valuation story now pegs fair value at $39 per share versus the latest close of $18.78, framing a wide gap that hinges on late stage autoimmune trial success and disciplined use of its cash runway.
The main thing that has to go right is that global Phase 3 trials of telitacicept in generalized myasthenia gravis and Sjögren's disease read out well and support regulatory approvals outside China.
The current valuation implies that the market does not fully credit the potential for telitacicept to support multibillion dollar sales across myasthenia gravis and Sjögren's disease.
See why 1 investors see Vor Biopharma as 52% undervalued.
Result: Fair Value of $39 (UNDERVALUED)
Still, Vor Biopharma’s story rests heavily on a single licensed drug. Any disappointing Phase 3 autoimmune readout could rapidly flip that undervaluation narrative.
Find out about the key risks to this Vor Biopharma narrative.
Next Steps
Sentiment around Vor Biopharma is split. This makes it a moment to move quickly, review the numbers, and decide where you stand using our 3 key rewards and 4 important warning signs
Looking for more investment ideas beyond Vor Biopharma?
If you want a fuller picture of what is possible for your portfolio, broaden your watchlist with other opportunities that share some of Vor Biopharma’s key traits.
- Target potential mispricings by scanning companies that combine stronger fundamentals with softer valuations using our 29 high quality undervalued stocks.
- Prioritise resilience first by focusing on businesses with healthier capital structures through the 31 resilient stocks with low risk scores.
- Hunt for underfollowed opportunities and surface lesser known quality stocks using the 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com